Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says [CNBC]
GoodRx Holdings, Inc. - Class A (GDRX)
Company Research
Source: CNBC
That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. It offers more evidence of the insatiable demand for a buzzy class of medications called GLP-1 and GIP agonists, which have hefty list prices of roughly $1,000 per month before insurance or savings cards. Prescription fills for blockbuster weight loss drugs in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments, according to data released Thursday by drug savings company GoodRx. The figures offer more evidence of the insatiable demand for a buzzy class of medications called GLP-1 and GIP agonists, which mimic gut hormones to suppress appetite and regulate blood sugar. That includes Novo Nordisk 's weight loss drug Wegovy and Eli Lilly 's obesity treatment Zepbound , which have hefty list prices of roughly $1,000 per month b
Show less
Read more
Impact Snapshot
Event Time:
GDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDRX alerts
High impacting GoodRx Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
GDRX
News
- Prof G's mother being ‘underinsured' fueled him to get rich — says America ‘focuses on shareholders' over wellbeing [Yahoo! Finance]Yahoo! Finance
- GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Seven Reasons Regular Health Checkups With Your Doctor Save You Money [Forbes]Forbes
- GoodRx Holdings, Inc. (NASDAQ: GDRX) had its price target lowered by analysts at Morgan Stanley from $7.00 to $6.00. They now have an "equal weight" rating on the stock.MarketBeat
- GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. CountiesBusiness Wire
GDRX
Earnings
- 11/7/24 - Beat
GDRX
Sec Filings
- 12/23/24 - Form 4
- 12/18/24 - Form SCHEDULE
- 12/18/24 - Form SCHEDULE
- GDRX's page on the SEC website